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Outcome of HCV infection after renal transplantation. The fate and
significance of hepatitis C virus (HCV) infection after renal transplan-
tation (TP) remain debated. We therefore evaluated the incidence and
outcome of HCV infection in 120 kidney graft recipients both at the time
of TP and 54 28(13 to 123) months later using ELISA-Il and RIBA-Il
immunoblot. Furthermore, the presence of anti-HCV antibodies at
follow-up was correlated with HCV viremia, as detected by the nested
polymerase chain reaction (PCR), and with chronically abnormal ALT
levels. At the time of TP, 17 patients (14.2%) had anti-HCV antibodies.
Compared to anti-HCV (—) patients, anti-HCV (+) patients had a
longer duration of pre-TP dialysis (P < 0.001) and had received more
pre-TP blood transfusions (P < 0.01). After an average follow-up of 48.5
24.7 (21 to 97) months, all these patients remained anti-HCV (+) but
only 10 were still RIBA "reactive" due to the loss of reactivity against
the 5-1-1, C100 and C33 (but not the C22) antigens. Five initially
anti-HCV (—) patients had become (+) at follow-up. Among the 22
patients anti-HCV (+) at follow-up, 20 had HCV-RNA detectable by
PCR but only 10 had elevated ALT. Ten out of 13 HBsAg (—) patients
with elevated ALT were anti-HCV (+). Our study indicates that
disappearance of ELISA-Il anti-HCV antibodies is rare in kidney
recipients and that HCV infection may also occur after TP. Anti-HCV
antibodies are likely to reflect a persisting infection as suggested by the
frequent detection of HCV-RNA. However, a substantial proportion of
transplanted patients with HCV infection have normal ALT levels.
HCV infection emerges as the main cause of liver dysfunction in kidney
graft recipients.
Infection by the hepatitis C virus (HCV) is common in kidney
graft recipients [1—5]. Its actual incidence is probably underes-
timated as it has been determined by poorly sensitive first-
generation serologic tests [6—11]. The fate and significance of
anti-HCV antibodies after renal transplantation (TP) remain
debated [4, 5, 12, 13]. In the present study second generation
tests were used to assess the incidence and the long-term
outcome of anti-HCV antibodies after TP in a cohort of 120
kidney recipients, the majority of whom had been dialyzed
before TP. In addition, we correlate the presence of the
anti-HCV antibodies at follow-up with HCV viraemia detected
by the nested polymerase chain reaction (PCR) and with liver
biochemical abnormalities.
Methods
Patients
Between January 1980 and May 1989, 259 patients were
transplanted and followed exclusively in our center for at least
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12 months. Among them we selected the first successive 120
patients (82 males/38 females; 119 Caucasian/i African), who
presented in our outpatient clinic between 1/2/90 and 1/6/90 and
for whom a pre-transplant serum was available. Among the
other 139 graft recipients, 10 had been lost to follow-up, 24 had
returned to dialysis, 15 had died, and 90 have still a functioning
graft.
The included patients had a mean post-TP follow-up of 54
28.2 (range 13 to 123) months. All had received at least three
units of packed red cells as part of a pre-transplant protocol. In
102, the number of blood units received before TP was re-
corded.
All patients received an initial 14 day course of antilympho-
cyte serum (ALSPressimmumR, Behringwerke, Germany) and
a combination of steroids and azathioprine (52 patients trans-
planted prior to 1985) plus cyclosporine (68 patients trans-
planted subsequently). Rejection episodes were treated with
three bolus injections of 500 mg of methylprednisolone, in
association with either antithymocyte serum (rabbit ATG,
Fresenius, France) or OKT3 (Orthoclone', Cilag). Thirteen out
of the 120 patients had not been dialyzed prior to TP.
Anti-HCV antibodies were detected by second generation
enzyme-linked immunosorbent assay (ELISA-Il, Ortho Diag-
nosis System). This test incorporates one antigen from both the
nonstructural NS3 (C33-c) and NS4 (C 100-3, including 5-1-1)
regions and a HCV-core-associated antigen (C22-3). Samples
were considered positive if the optical density reading/cut-off
ratio was equal or greater than one. To assess the specificity of
the ELISA, a second generation confirmation recombinant
immunoblot assay (RIBA-Il, Ortho Diagnosis) was performed
in ELISA-II anti-HCV repeatedly (duplicate) positive sera. In
this test, the ClOO-3, 5-1-1, C33-c, C22-3 and the superoxide
dismutase have been coated in bands on nitrocellulose strips.
According to the rating system proposed by the manufacturer,
each antigen band's intensity was compared with positive
control bands, and a response of 1 + or greater (up to 4+) to any
two or more antigens was interpreted as a "reactive" confir-
mation test. ELISA-II positive samples reactive with only one
of the HCV antigens were considered "indeterminate".
The anti-HCV status was tested on the serum obtained at TP
and at the latest post-TP follow-up.
Five initially ELISA-Il negative patients developed anti-
HCV antibodies after TP. In the absence of serum from the
donor, the anti-i-ICY status of the recipient of the heterolateral
kidney from the same donor was evaluated as well as all
post-transplant blood transfusions. Whenever possible, both
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Table 1. Post-TP evolution of RIBA-Il pattern in 22 anti-HCV ELISA-!! positive patients
At transplantation
FU
months
At follow-up
Patient Intensity of staining
Result
Intensity of staining
no. 5-1-1 Cl00 C33 C22 5-1-I Cl00 C33 C22 Result
1 ++ — ++++ — R 34 — — +++ ++ R
2 ++++ ++++ ++++ -i-+++ R 65 ++ ++ +-I- ++++ R
3 +++ +++ + ++++ R 31 + + ++ ++++ R
4 +++ +1— ++ + R 22 + — +1— +1— I
5 — — ++++ R 62 — — +++ +++ R
6 +++ — ++++ ++-i-+ R 54 — — + +++ R
7 — — +++÷ -I-+++ R 25 — — +++ ++++ R
8 ++++ + ++++ ++++ R 35 + — +1— ++++ R
9 ++++ ++++ ++++ ++++ R 84 — — +++ ++++ R
10 — — +-1-++ +++ R 33 — — ++++ — I
11 ++++ ++++ ++++ ++++ R 21 ++++ ++++ ++++ ++++ R
12 — — ++++ ++++ R 76 — — ++++ ++++ R
13 — — ++++ R 53 — — — ++++ I
14 — +1— +++ ++++ R 28 — — — ++++ I
15 +++ + ++++ ++++ R 97 — — — ++++ I
16 — — — ++++ I 80 — — — ++++ I
17 — — +1— ++++ I 25 — — — +++-l- I
18 — — — — NR 58 ++++ + +++ ++++ R
19 — — — — NR 41 ++ +++ + ++++ R
20 — — — — NR 67 ++++ — — + R
21 — — — — NR 55 ++ ++++ ++++ ++++ R
22 — — — — NR 75 +1— — — ++++ I
Abbreviations are: R, reactive; I, indeterminate; NR, nonreactive (see Methods section); FU, follow-up.
ALT and anti-HCV status of the blood donors of these trans-
fusions were retrospectively obtained.
HCV-RNA was detected on follow-up sera with the nested
polymerase chain reaction (PCR) with primers derived from the
5'-noncoding highly conserved region of the HCV genome [14]
in ELISA-Il positive patients and in patients with "unex-
plained" (without marker for both hepatitis B and C) liver
dysfunction. Briefly, HCV-RNA was extracted from 50 d
serum using the acid guanidinium-thiocyanate-phenol-chioro-
form method [15]. RNA was redissolved in S sl diethylpyrocar-
bonate treated water with 10 units placental RNAase inhibitor
(Boehringer). Each serum was coextracted with one H20
sample as negative control. Mter the transcription step a double
amplification was done using two primer pairs as described by
Imberti et al [16]. The specificity of PCR products was con-
firmed by Southern blot hybridization under stringent condi-
tions with an internal oligonucleotide probe (position from —185
to —148) enzymatically labeled with digoxigenin using Dig-
System (Boehringer Mannheim). Results were recorded only if
the samples and the negative controls were reproducible in at
least two independent extractions and two independent double
amplifications.
The presence of liver disease was assessed in 102 patients in
whom at least six alanine aminotransferase (ALT) determina-
tions were available during follow-up. Chronic liver dysfunction
was diagncsed if ALT levels were above the normal range in at
least 50% of the samples.
Hepatitis B (HB) markers, including HBs Ag, anti-HBc and
anti-HBs, were assayed by radioimmunoassay using commer-
cially available kits (AUSRIA II, CORAB, AUSAB, Abbott
Laboratories, North Chicago, illinois, USA). None of the HBs
Ag negative patients in whom anti-HBc antibodies were de-
tected had HBV-DNA detectable by a liquid phase molecular
hybridization test (HBV-DNA, Abbott). The hepatitis B status
was determined at the time of TP and at the latest post-TP
follow-up.
Results are expressed as mean SD. Unpaired Student's
t-test was used for statistical analysis of the data, as indicated.
P < 0.05 was considered of statistical significance.
Results
Anti-HCV status at the time of TP
At the time of TP, 17 patients (14.2%) were ELISA-JI
positive; 15 had a reactive and two an indeterminate RIBA-Il.
Duration of dialysis was significantly longer (P < 0.001) in the
anti-HCV positive (66.2 49.2 months) than in the anti-HCV
negative patients (23.5 23.1 months). Anti-HCV antibodies
were not detected in the thirteen patients who had never been
dialyzed. Anti-HCV positive patients had received significantly
more (P < 0.01) pre-transpiant blood transfusions (15 19.6 U)
than the anti-HCV negative patients (6.3 5.6 U).
Anti-HCV status at follow-up.
The 17 ELISA-lI anti-HCV positive patients remained posi-
tive after an average follow-up of 48.5 24.7 (range 21 to 97)
months. The number of reactive bands of the RIBA-Il per
patient tended to decrease over time since ELISA-Il positive
patients had an average of 2.7 reactive bands on pre-transplant
RIBA-Il versus 2.0 on follow-up RIBA-Il (Table 1, Fig. 1). The
decrease in the intensity of the RIBA-Il positivity was observed
for the 5-1-I, ClOO and C33 but not the C22 antigens. As a
result, five out of the 15 RIBA-Il reactive patients at the time of
TP had become RIBA-Il indeterminate at the end of follow-up
56.6 31.7 months (range 25 to 97) later.
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B
Presence of anti-HCV
antibodies (N = 21)
Absence of anti-HCV
antibodies (N = 81)
HB5Ag(+) HBsAg(—)(N = 2) (N = 19)
HBsAg(+) HB5Ag(—)(N = 7) (N = 74)
Abnormal ALT 1 10 5 3
Normal ALT 1 9 2 71
Ninety-eight initially ELISA-Il negative patients remained so
after a mean follow-up of 55 23.2 (range 13 to 123) months.
In the remaining five initially ELISA-Il negative patients,
anti-HCV antibodies were detected at follow-up, an average of
59.2 12.8 (range 41 to 75) months afterTP. In these five cases
anti-HCV status from the graft donors remained unknown.
However, none of the recipients of the controlateral kidney had
clinical and biological evidence of HCV infection, but this was
confirmed by ELISA-Il testing in a single case. These five
patients had received 4, 7, 4, 3 and 5 units of blood, respec-
tively, after TP. Anti-HCV status (ELISA-Il) was negative in
five out of the 22 donors of these 22 blood units, whereas ALT
were normal in seven others.
HCV-RNA detection at follow-up by PCR
Among the 22 patients who were ELISA-Il positive at
follow-up, 20 had HCV-RNA detectable by PCR. The two
others, although ELISA-Il positive, were RIBA-Il indetermi-
nate (patients 4 and 14 in Table 1).
Anti-HCV status and liverfunction test evaluated by ALT
The relation between ALT levels and the HBs Ag and
anti-HCV status is presented in Table 2. Nineteen patients had
a sustained rise in ALT levels. HBs Ag and/or anti-HCV
antibodies were present in 16 (84%), leaving only three patients
without these markers. Still, when the serum of these three
patients was tested for HCV-RNA, one was found to be
positive.
Among the 19 anti-HCV positive HbsAg negative patients, 10
only (53%) had elevated ALT levels. In none of them was liver
disease-related morbidity or mortality observed during follow-
up.
Discussion
The prevalence of anti-HCV antibodies evaluated with
EL1SA-Il prior to renal TP is 14%, a value comparable with that
obtained in several studies performed with ELISA-Il assays in
hemodialyzed patients in non-endemic areas of HCV infection
[7, 9, 17] and in the study of Chan in Asiatic renal transplant
recipients [18]. In dialyzed patients, the number of pre-trans-
plant blood transfusions and duration of hemodialysis are the
most important risk factors for HCV infection [7, 9, 17]; this
observation is confirmed in kidney graft recipients on the basis
of first [1—3] or second generation tests (this study and Chan's
report) [18].
Using the second generation ELISA tests, no negative anti-
HCV antibodies were observed after an average post-TP fol-
low-up of 54 (range 13 to 123) months. Chan et al reported the
same observation in patients followed for a shorter duration
[18]. This finding is in contrast with the progressive loss of
ELISA-I anti-HCV antibodies reported after TP in longitudinal
studies [4, 5], and with the downward trend of ELISA-I
anti-HCV positivity observed after TP in cross sectional studies
[1, 2, 13]. This discrepancy is explained by our longitudinal
determination of several antibodies by RIBA-Il. Antibodies
againt both C100 and 5-1-1 antigens, the only targets of the
ELISA-I test, may actually disappear after TP (Table 1).
Reactivity of antibodies declined occasionally against C33 but
rarely against C22 (Table 1, Fig. 1). In five patients, only
anti-C22 antibodies persisted, resulting in an indeterminate
RIBA.
PCR detected HCV-RNA in 15 out of the 17 initially
ELISA-Il positive patients, including those five patients with
indeterminate RIBA-Il. This suggests that antibodies against
HCV are likely to reflect persisting viremia in this high-risk
population. This conclusion might, however, not apply to a low
risk popu1atic'. such as healthy blood donors infected by HCV
[19, 20]. HCV-RNA was not detected in two ELISA-lI positive
RIBA-Il indeterminate patients. Such a feature might be indic-
ative of either the recovery from HCV infection as recently
suggested, under similar conditions in two hemophiliacs [211 or
0
5-1-1 C100 C33 C22
At transplantation
Table 2. Assessment of liver dysfunction (N = 102)
Fig. 1. Evolution of the RIBA-Il reactivity in5-1-1 Cl 00 C3 C22 17 patients ELISA-lI positive at the time of
TP. Fewer p tients are positive for 5-1-1,
At follow-up C100 and C33 antigens at follow-up.
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non-detectable viremia due to low phase replication or muta-
tion(s) of the virus [19].
It is of note that the prevalence of viremia might have been
slightly underestimated; Chan et a! found that 4 out of 166
(2.4%) of their ELISA-Il negative patients had a positive PCR
[18].
Five patients were infected by the HCV after TP. The source
of infection cannot be traced with certainty. The graft itself is a
potential candidate even if its importance remains disputed [22,
23]. Unfortunately anti-HCV status of the graft donor could not
be ascertained and information from the recipients of the
controlateral kidneys was incomplete. Blood transfusions re-
ceived at the time of TP are a more likely source of contami-
nation. Serologic data obtained from the blood bank did not
permit testing of this hypothesis. Nosocomial or sexual trans-
mission of the virus can also occur, and such modes of
contamination should be kept in mind [24, 25]. Finally, HCV
infection might have occurred prior to TP, the patients being
PCR positive but ELISA-lI negative at the time of TP. Unfor-
tunately, pre-TP sera of the seroconverters were not suitable
for PCR analysis.
An interesting finding of our study is that in HBs Ag-negative
kidney recipients, HCV infection is the main cause of otherwise
unexplained liver dysfunction. ELISA-JI anti-HCV were de-
tected in 10 out of 13 HBs Ag (—) patients (77%) with chroni-
cally elevated ALT. With the less sensitive ELISA-I test, we
had reported anti-HCV antibodies in only 11 out 19 HBsAg (—)
patients (58%) with abnormal ALT [1].
It is of note that abnormal serum ALT levels are a poor
predictive test for HCV infection. Indeed, nine out of our 19
ELI SA-lI anti-HCV positive HBsAg negative patients (47%)
did not exhibit abnormal ALT in spite of HCV-RNA positivity.
Likewise, Chan et a! found that 30.4% of their viremic kidney
graft recipients had normal serum ALT [18]. The same conclu-
sion was reached in healthy blood donors by Alberti et al who
showed that 9 out of 16 patients with HCV antibodies had
normal ALT, despite histological evidence of chronic hepatitis
[26].
In agreement with the observations of Stempel et al [27],
during the five year follow-up, HCV infection led only to
elevation of ALT levels in 53% of the patients without any
evidence of liver morbidity or mortality. This finding stands in
contrast with our previous observations of a significant mortal-
ity in kidney recipients infected by the hepatitis B virus [28].
The weaker aggressivity of HCV is illustrated in two recent
studies which show the presence of normal liver histology in
spite of the persistence of HCV viremia [29, 30].
In summary, our study indicates first that the complete
disappearance of ELISA-Il anti-HCV antibodies is rare in
kidney recipients. The presence of ELISA-Il anti-HCV anti-
bodies in this population appears to reflect a persisting infection
as demonstrated by the frequent HCV-RNA positivity.
Second, HCV infection may occur after renal TP, probably as
the result of contamination either by the graft or by periopera-
tive blood transfusions.
Third, HCV infection emerges as the main cause of previ-
ously unexplained liver dysfunction in kidney recipients. How-
ever, a substantial proportion of transplanted patients with
HCV infection have normal ALT levels. Finally, HCV-RNA
may be the only detectable marker of HCV infection.
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